// App-Quantinova.ai

: TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion

Researchers

Presenter

  • Maria Julia Montoro Gómez

Principal Investigators

  • Laura Palomo

  • Pablo Vidal

  • Francisco Fuster-Tormo

  • Esperanza Such

  • Margarita Ortega

  • Teresa Gonzalez

  • Felix Lopez-Cadenas

  • Sara Garcia-Avila

  • Nieves Garcia-Gisbert

  • Elvira Mora Casterá

  • Eugenia Rivero

  • Francesc Bosch

  • Andres Jerez

  • Maria Diez-Campelo

  • Francesc Sole

  • David Valcarcel

Medical Centers

  • Department of Hematology, University Hospital Vall d'Hebron, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • MDS Group. Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

  • Hematology and Medical Oncology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain, MURCIA, Spain

  • Hematology Department, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain

  • Salamanca Universitu Hospital, Salamanca, Spain

  • Department of Hematology, University Hospital Arnau de Vilanova, Lleida, Spain

  • Hematology Department., Hospital Universitario y Politécnico La Fe, Valencia, Spain

  • Group of Applied Clinical Research in Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain

  • Department of Hematology, University Hospital of Salamanca, Salamanca, Spain

  • Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Calreticulin

  • Nucleophosmin 1

  • CCAAT enhancer binding protein alpha

  • Colony stimulating factor 3 receptor

  • Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • E3 ubiquitin-protein ligase CBL

  • Enhancer of zeste homolog 2

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

  • KRAS proto-oncogene, GTPase

  • DNA methyltransferase 3 alpha

  • ETV6-RUNX1

  • GTPase Nras

  • Fms related tyrosine kinase 3

  • Isocitrate dehydrogenase 1

  • WT1 Transcription Factor

  • Tet methylcytosine dioxygenase 2

  • Isocitrate dehydrogenase 2

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • TP53

  • EZH2

Outcome

  • N/A

Study Design

  • KRAS

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved